Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.82 |
| ▸ | RET | P07949 | 7/20 | 0.82 |
| ▸ | KIF5B | P33176 | 5/20 | 0.82 |
| ▸ | JAK3 | P52333 | 2/20 | 0.76 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.76 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.76 |
| ▸ | EGFR | P00533 | 12/20 | 0.73 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.73 |
| ▸ | GAK | O14976 | 1/20 | 0.73 |
| ▸ | STK10 | O94804 | 1/20 | 0.73 |
| ▸ | FLT3 | P36888 | 1/20 | 0.73 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.73 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.73 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.73 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.73 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.73 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.73 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.72 |
| ▸ | CLK1 | P49759 | 1/20 | 0.72 |
| ▸ | LCK | P06239 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651286 | 0.90 | KDR (1.00) | KDRRETKIF5BJAK3ABCG2 | |
| Hydrochloric Acid SCHEMBL7859467 | 0.89 | KDR (0.98) | KDRRETKIF5BJAK3ABCG2 | |
| SCHEMBL5565204 | 0.88 | KDR (0.79) | KDRRETKIF5BJAK3ABCG2 | |
| SCHEMBL7112009 | 0.86 | KDR (0.76) | KDRRETKIF5BJAK3ABCG2 | |
| SCHEMBL5864719 | 0.86 | KDR (0.82) | KDRRETKIF5BJAK3ABCG2 | |
| SCHEMBL5864546 | 0.86 | KDR (0.82) | KDRRETKIF5BJAK3ABCG2 | |
| SCHEMBL29651 | 0.86 | JAK3 (1.00) | KDRRETKIF5BJAK3ABCG2 | |
| SCHEMBL29711485 | 0.86 | JAK3 (1.00) | KDRRETKIF5BJAK3ABCG2 | |
| SCHEMBL29372372 | 0.86 | JAK3 (1.00) | KDRRETKIF5BJAK3ABCG2 | |
| Whi-P131 SCHEMBL29295 | 0.84 | EGFR (1.00) | KDRRETKIF5BJAK3ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10548897-B2 | KSR antagonists | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-02-04 | — | — | US | disclosed |
| WO-2016168704-A1 | KSR ANTAGONISTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2016-10-20 | — | — | WO | disclosed |
| US-7081461-B1 | Quinazoline compounds and pharmaceutical compositions containing them | ASTRAZENECA AB (SE) | 2006-07-25 | — | — | US | disclosed |
| EP-1218356-A1 | QUINAZOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021594-A1 | QUINAZOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | disclosed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548897-B2 | KSR antagonists | KSR1, KSR2, KRAS | KDR 1123/4885RET 321/4885KIF5B 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.